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Abstract
In recent years, autoimmunity has been increasingly recognised as an important 
cause of encephalitis. Many different antibodies are now known to target antigens on 
the neuronal surface, and some of these are associated with characteristic clinical 
presentations, although seronegative cases are also recognised. Autoimmune 
encephalitis may mimic other conditions, including primary psychiatric disorders, 
particularly early in the disease. Because early immune treatment of autoimmune 
encephalitis improves patient outcomes, and indeed many make a good recovery, it 
is important to recognise these syndromes promptly. 
Introduction
Encephalitis, a disease of inflammation of the brain, may be caused by an infectious 
pathogen or by autoimmune processes. Over the last 5-10 years encephalitis 
associated with antibodies against neuronal surface antigens has been increasingly 
recognised. 
Autoimmune encephalitis is thought to account for at least 20 percent of cases of 
encephalitis,1 therefore the UK might expect approximately 1000 cases/year.2 Many 
patients with autoimmune encephalitis (AE) have the capacity to make a good 
recovery if treated appropriately, despite a stormy disease course. Therefore, it is 
important to have a high index of suspicion to recognise cases early. However, the 
myriad antibodies now available for testing have the potential to cause confusion.
This CME article will explore recent developments in AE research and practical 
implications for physicians. Antibodies associated with intracellular antigens are 
often paraneoplastic and immune-therapy responses may be limited. Also, some 
antibodies, such as thyroid peroxidase antibodies, are thought to represent an 
epiphenomenon. Therefore, this article will focus on encephalitis in adults with 
antibodies directed against neuronal surface antibodies, where early diagnosis and 
management can substantively improve outcomes.

































































The spectrum of clinical presentations associated with AE is wide and partly reflects 
the antibody involved (table 1). The most recognisable clinical syndromes are limbic 
encephalitis and NMDA-R encephalitis.
Limbic encephalitis, reflecting inflammation of the medial temporal lobe, may present 
with changes in behaviour, seizures or memory difficulties. Two of the most common 
and well characterised antibodies which are associated with limbic encephalitis are 
those directed against leucine-rich glioma-inactivated 1 (LGI1) and Contactin-
associated protein-like 2 (CASPR2). AE associated with LGI1 antibodies generally 
affects older patients and is unusual in those <40 years. LGI1 antibodies may be 
associated with faciobrachial dystonic seizures: brief jerking movements affecting 
ipsilateral arm and face, which when seen are highly specific to LGI1 and may 
precede the onset of encephalitis, however they may not be present in many.3  
Hyponatraemia is also a common finding.4 CASPR2 antibody encephalitis can 
present with a crossover of central and peripheral nervous system features including 
memory difficulties, sleep disturbances and peripheral nerve hyperexcitability 
syndromes. Testing for VGKC-complex antibodies should now be abandoned in 
favour of testing for LGI1 and CASPR2 antibodies, which target proteins associated 
with the ion channel. VGKC positivity in the absence of LGI1 or CASPR2 antibodies 
has been reported in a heterogenous group of clinical syndromes, but is not thought 
to be a true marker of disease.5 
NMDA-R encephalitis most often affects children and younger adults, has a 4:1 
female predominance and is associated with ovarian teratoma in around half of the 
females. The disorder begins with abnormal behaviour, often with psychotic or 
affective features, developing by one month into a characteristic clinical picture. This 
may include seizures, movement disorder (classically orofacial dyskinesia, but limb 
dyskinesia/chorea is often predominant), reduced conscious level and autonomic 
dysfunction (particularly bradycardia/tachycardia, hyperthermia and fluctuating blood 
pressure).6 NMDA-R encephalitis can occasionally be triggered by herpes simplex 
virus (HSV) encephalitis: in a recent prospective study of 51 patients with HSV 
encephalitis, 14 developed secondary autoimmune encephalitis associated with 
neuronal antibodies, although 3 also developed NMDA-R antibodies in the absence 
of clinical evidence of encephalitis.7
Other, more recently described syndromes are associated with antibodies against γ-
aminobutyric acid receptors (GABAR) type A or B, the α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid receptor (AMPAR) and dipeptidyl-peptidase-like protein 6 
(DPPX) (Table 1).
Clinicians should be aware of formes frustes within these classical syndromes, for 
example some patients incipient NMDA-R encephalitis may present with first episode 
psychosis or prominent movement disorder.

































































Patients presenting with symptoms suggestive of encephalitis should be admitted 
urgently and undergo lumbar puncture and neuroimaging. The main concern at the 
outset is to exclude an infectious cause such as HSV, which can cause rapidly 
progressive brain oedema, necrosis and death. Aciclovir treatment in HSV 
encephalitis is a life-saving intervention.Several antibody-associated encephalitides, 
particularly NMDA-R encephalitis, can present similarly to primary psychiatric 
illness. “Red flag” early features for AE include an infectious prodrome, rapid 
progression, movement disorder, focal neurological signs, seizures or unexplained 
hyponatraemia.8 
Although autoimmune encephalitis is now usually a positive diagnosis, other mimics 
of AE should be excluded, including primary central nervous system (CNS) 
lymphoma, neurosarcoidosis, CNS vasculitis, tumours, genetic epilepsy syndromes, 
mitochondrial encephalomyopathies, and prion disease.
CSF findings are often abnormal in AE, with a mild lymphocytic pleocytosis and/or 
moderately raised CSF protein. However, a completely normal CSF occurs in up to a 
third of patients and does not exclude the diagnosis.9
Neuroimaging with magnetic resonance imaging (MRI) is essential, although this 
may also be normal in up to a third of cases.10 In general, MRI findings are 
nonspecific although medial temporal lobe signal change frequently occurs in limbic 
encephalitis (e.g. figure 1 A and B). 
Electroencephalography (EEG) often reveals encephalopathic changes which can 
support the diagnosis but are nonspecific. Caution is required as psychiatric and 
antiepileptic drugs can cause similar features.11 EEG is helpful in diagnosing non-
convulsive status epilepticus, or in distinguishing seizures (e.g. epilepsia partialis 
continua (EPC)) from a movement disorder. NMDA-R encephalitis may be 
associated with characteristic extreme delta brush pattern (figure 1 C).
Antibody testing for encephalitis is a rapidly evolving area of neuroimmunology. 
Certain autoimmune encephalitides, particularly those associated with NMDA-R and 
LGI1 antibodies, present with recognisable clinical syndromes and diagnostic 
suspicion may already be high so that antibody testing can be targeted. In other 
cases without distinguishing features, testing for a wider range of antibodies may be 
necessary, in consultation with a neurologist and neuroimmunology laboratory. 
Panels of immunofluorescence tests have been developed commercially and their 
role is still evolving, considering the balance between increased chance of detecting 
a pathogenic antibody versus the potential for false positives. Antibodies have 
hitherto mostly been tested in serum. However, intrathecal antibody synthesis occurs 
in most forms of AE and, particularly for NMDA-R antibodies, CSF testing is more 
specific than serum and should be undertaken where clinical suspicion is high and in 
challenging cases. 
Consensus criteria also allow for a diagnosis of ‘seronegative AE’, based on clinical 
features in the absence of antibodies which may respond to immune therapy.6,12 (box 
1) 
































































Because of the paraneoplastic associations of several antibodies, investigation for 
malignancy is crucial. Computed tomography of the chest, abdomen, and pelvis is 
indicated in all patients with suspected AE. For those with particular associations, 
such as GABABR, positron emission tomography scanning is advised and, if 
negative, should be repeated at 3-6 months.13 Additionally, in NMDA-R encephalitis, 
because of the association with teratoma, ultrasound of the ovaries or testes should 
be performed.
4. Management and outcome
Evidence for optimal management of AE is largely based on retrospective studies, 
together with principles adapted from other antibody mediated diseases, e.g. 
myasthenia gravis. Patients with encephalitis should be managed at a centre with 
appropriate facilities and specialist expertise, ideally a regional neuroscience centre, 
in accordance with the national guidelines of the Association of British Neurologists 
and British Infection Association.
First line therapy, aimed at reducing antibody levels rapidly, normally comprises 
intravenous corticosteroids often in combination with intravenous immunoglobulin or 
plasma exchange. In those who fail to respond, more aggressive immune therapy is 
usually started, with concomitant higher risk of adverse effects, including 
cyclophosphamide or rituximab.14 In NMDA-R encephalitis other agents such as 
bortezomib have been used in a small number of refractory cases. Relapses may 
occur when immune therapy is reduced, or may reflect tumour recurrence or 
persistence of missed tumour.15
Starting immune therapy early has been associated with improved outcome in 
NMDA-R encephalitis in retrospective series. Also, in those who fail to respond to 
first-line therapy, moving to more aggressive second line treatments is associated 
with better outcome and reduced rate of relapse.16 In patients with ovarian teratoma, 
tumour resection is associated with faster rate of recovery and reduced relapse 
rate.16 
LGI1 encephalitis generally responds well to first-line treatment, particularly 
corticosteroids, and outcomes are generally good, however, in the long-term 
cognitive problems are common.17,18
Patients with autoimmune encephalitis often require extensive supportive care, 
including prolonged intensive care unit stays. Issues may include managing 
seizures, autonomic instability, infective complications, and agitation. Antipsychotic 
medications may be required, but should be used with caution due to the risk of 
extrapyramidal side effects or neuroleptic malignant syndrome, which may be higher 
in NMDA-R encephalitis.19
With appropriate treatment, outcome overall compares favourably with infectious 
encephalitis, with >80% of patients with NMDA-R encephalitis having no more than 
slight disability (modified Rankin Scale 2) at 2 years.16 However, evidence is 
emerging that subtle neurocognitive/psychosocial issues may be more prevalent 
































































than previously appreciated.20 Support from psychology/counselling services and 
charitable groups, such as the Encephalitis Society, is vital in the recovery phase. 
5. Conclusions
It is increasingly possible to make a positive diagnosis of AE given consensus 
clinical criteria and increased availability of antibody tests. However, this relies on a 
high index of suspicion, especially in those presenting with primarily psychiatric 
features. The diagnosis is often supported by the development of ‘neurological’ 
features, such as movement disorders and seizures, laboratory tests, and MRI, but 
these may be normal in some. Antibody testing should be organised in consultation 
with a neurologist and neuroimmunology laboratory, with a pragmatic strategy based 
on careful clinical assessment. Even in the absence of antibodies, it may be possible 
to make a syndromic diagnosis.
Many with AE have a go d outcome with early immune therapy, tumour resection if 
needed, and supportive care. Randomised controlled trials are needed to guide 
treatment strategies.
Key points
Autoimmune encephalitis should be a key part of the differential diagnosis in patients 
with alterations in cognition, consciousness, personality, or behaviour.
Antibody testing should be guided by recognisable clinical syndromes, but also 
should account for the expanding numbers of recognised antibodies and overlapping 
phenotypes. 
Autoimmune encephalitis may present sub-acutely with normal or subtly abnormal 
CSF findings and neuroimaging.
Despite severe symptoms and long ITU stays, the outcome of AE is good in most 
cases if early immune therapy is given. 
The optimum first and second line treatment strategy for AE is unclear and well-
designed clinical trials are needed.  
Key words
Neuroimmunology, encephalitis, autoimmunity, NMDA-R encephalitis, limbic 
encephalitis.

































































































































1. A 72 year old man presented with a 3 month history of gradually worsening 
memory difficulties and unusual behaviour, including emotional lability. Family had 
noticed some jerky movements of his left arm and face on a few occasions over the 
preceding three weeks. On examination he was alert but distracted and his mini 
mental state examination (MMSE) score was 9/30. MRI brain showed age-
appropriate brain atrophy with T2 signal hyperintensity in the right medial temporal 
lobe. CSF showed white cell count of 8/mm3 (normal range <5), protein of 0.7 g/L 
(normal <0.5) with normal glucose ratio. Which antibody is most likely to be found in 







The patient had limbic encephalitis, with typically prominent memory and cognitive 
problems with a subacute onset and inflammation in the medial temporal lobe. The 
most common antibody identified in this situation is LGI1, and the jerky movements 
seen by his family are suspicious for faciobrachial dystonic seizures which may be 
pathognomonic for this disorder.
2. A 23 year old woman was referred from the psychiatric hospital for assessment of 
suspected seizures and hyperthermia. She had been an inpatient there for 6 weeks 
receiving treatment for a first episode of psychosis with neuroleptic medications. On 
clinical examination she was drowsy, had writhing movements of her left hand and 
was repeatedly protruding her tongue. Her temperature was 38.2oC and heart rate 
was 135. MRI brain was normal and CSF showed white cell count of 35 (normal 
range <5), protein of 0.4 g/L (normal range <0.5). CT scan of the chest, abdomen 
and pelvis revealed an ovarian mass. What is the most likely diagnosis?
A. Juvenile myoclonic epilepsy
B. LGI1 encephalitis 
C. NMDA-R encephalitis
D. Primary psychiatric diagnosis 


































































The combination of psychiatric features with autonomic instability, movement 
disorder and encephalopathy is characteristic of NMDA-R encephalitis. The 
presence of CSF pleocytosis, and an ovarian mass (most likely a teratoma) is also 
supportive, and the mass should be resected urgently. MRI brain is frequently 
normal in AE. Juvenile myoclonic epilepsy presents with myoclonus (which are not 
writhing movements) and generalised seizures. LGI1 encephalitis causes a limbic 
encephalitis, usually in older adults. Tardive dyskinesia would be unusual after only a 
few weeks of treatment and does not explain the addition features. 
3. A 52 year old woman, previously fit and well, presented to the emergency 
department with a 4 day history of flu-like illness and increasing drowsiness, with a 
single generalised tonic-clonic seizure. Her family reported that she had been 
agitated and aggressive when rousable. On examination her Glasgow coma scale 
(GCS) score was 10 (E3, V2, M5), she was moving all four limbs. CT brain showed 
subtle diffuse hypodensity in bilateral medial temporal lobes of uncertain aetiology, 
more prominent on the left. What is the most appropriate initial management?
A. Intravenous alteplase
B. Intravenous corticosteroids
C. Intravenous immunoglobulin 
D. Plasma exchange
E. Intravenous aciclovir 
Answer: E
In a patient with acute decrease in conscious level and seizures, infectious 
encephalitis (most commonly HSV encephalitis in the UK) is the most important 
diagnosis to rule out. Lumbar puncture (LP) should be performed urgently, and 
intravenous aciclovir (which decreases morbidity and mortality) should be given 
either immediately after the LP, or before if LP is delayed for any reason. 
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Psychiatric features followed by 
movement disorder (classically 
orofacial dyskinesia), seizures, 
encephalopathy and autonomic 
dysfunction
About 50% of female 












Sleep disorders (insomnia, sleep-
wake cycle disturbance), 
peripheral nerve hyperexcitability, 
ataxia 
<5%, various tumours
GABAAR Children or 
adults
1:1 Seizures Thymoma in 30%
GABABR Older adults 1:1.5 Seizures, amnesia SCLC in 50%
AMPAR Older adults 2:1 Amnesia 65%
Breast, SCLC, 
thymoma




NMDAR = N-methyl -aspartate receptor; LGI1 = leucine rich glioma inactived-1; CASPR2 = contactin-
associated protein-like 2; GABAAR = γ-aminobutyric acid type A receptor; GABABR = γ-aminobutyric 
acid type B receptor; AMPAR = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; 
DPPX = dipeptidyl-peptidase-like protein 6; SCLC = small cell lung cancer.
































































Box 1. Diagnostic criteria for possible autoimmune encephalitis 6
Diagnosis can be made when all three of the following criteria have been 
met:
1. Subacute onset (rapid progression of less than three months) of working 
memory deficits (short-term memory loss), altered mental status, or psychiatric 
symptoms.
2. At least one of the following:
 New focal CNS findings
 Seizures not explained by a previously known seizure disorder
 CSF pleocytosis
 MRI features suggestive of encephalitis
3. Reasonable exclusion of alternative causes (e.g. HSV encephalitis).
CNS = central nervous symptoms; CSF = cerebrospinal fluid; MRI = magnetic resonance 
imaging.
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Abstract
In recent years, autoimmunity has been increasingly recognised as an important 
cause of encephalitis. Many different antibodies are now known to target antigens on 
the neuronal surface, and some of these are associated with characteristic clinical 
presentations, although seronegative cases are also recognised. Autoimmune 
encephalitis may mimic other conditions, including primary psychiatric disorders, 
particularly early in the disease. Because early immune treatment of autoimmune 
encephalitis improves patient outcomes, and indeed many make a good recovery, it 
is important to recognise these syndromes promptly. 
Introduction
Encephalitis, a disease of inflammation of the brain, may be caused by an infectious 
pathogen or by autoimmune processes. Over the last 5-10 years encephalitis 
associated with antibodies against neuronal surface antigens has been increasingly 
recognised. 
Autoimmune encephalitis is thought to account for at least 20 percent of cases of 
encephalitis,1 therefore the UK might expect approximately 1000 cases/year.2 Many 
patients with autoimmune encephalitis (AE) have the capacity to make a good 
recovery if treated appropriately, despite a stormy disease course. Therefore, it is 
important to have a high index of suspicion to recognise cases early. However, the 
myriad antibodies now available for testing have the potential to cause confusion.
This CME article will explore recent developments in AE research and practical 
implications for physicians. Antibodies associated with intracellular antigens are 
often paraneoplastic and immune-therapy responses may be limited. Also, some 
antibodies, such as thyroid peroxidase antibodies, are thought to represent an 
epiphenomenon. Therefore, this article will focus on encephalitis in adults with 
antibodies directed against neuronal surface antibodies, where early diagnosis and 
management can substantively improve outcomes.

































































The spectrum of clinical presentations associated with AE is wide and partly reflects 
the antibody involved (table 1). The most recognisable clinical syndromes are limbic 
encephalitis and NMDA-R encephalitis.
Limbic encephalitis, reflecting inflammation of the medial temporal lobe, may present 
with changes in behaviour, seizures or memory difficulties. Two of the most common 
and well characterised antibodies which are associated with limbic encephalitis are 
those directed against leucine-rich glioma-inactivated 1 (LGI1) and Contactin-
associated protein-like 2 (CASPR2). AE associated with LGI1 antibodies generally 
affects older patients and is unusual in those <40 years. LGI1 antibodies may be 
associated with faciobrachial dystonic seizures: brief jerking movements affecting 
ipsilateral arm and face, which when seen are highly specific to LGI1 and may 
precede the onset of encephalitis, however they may not be present in many.3  
Hyponatraemia is also a common finding.4 CASPR2 antibody encephalitis can 
present with a crossover of central and peripheral nervous system features including 
memory difficulties, sleep disturbances and peripheral nerve hyperexcitability 
syndromes. Testing for VGKC-complex antibodies should now be abandoned in 
favour of testing for LGI1 and CASPR2 antibodies, which target proteins associated 
with the ion channel. VGKC positivity in the absence of LGI1 or CASPR2 antibodies 
has been reported in a heterogenous group of clinical syndromes, but is not thought 
to be a true marker of disease.5 
NMDA-R encephalitis most often affects children and younger adults, has a 4:1 
female predominance and is associated with ovarian teratoma in around half of the 
females. The disorder begins with abnormal behaviour, often with psychotic or 
affective features, developing by one month into a characteristic clinical picture. This 
may include seizures, movement disorder (classically orofacial dyskinesia, but limb 
dyskinesia/chorea is often predominant), reduced conscious level and autonomic 
dysfunction (particularly bradycardia/tachycardia, hyperthermia and fluctuating blood 
pressure).6 NMDA-R encephalitis can occasionally be triggered by herpes simplex 
virus (HSV) encephalitis: in a recent prospective study of 51 patients with HSV 
encephalitis, 14 developed secondary autoimmune encephalitis associated with 
neuronal antibodies, although 3 also developed NMDA-R antibodies in the absence 
of clinical evidence of encephalitis.7
Other, more recently described syndromes are associated with antibodies against γ-
aminobutyric acid receptors (GABAR) type A or B, the α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid receptor (AMPAR) and dipeptidyl-peptidase-like protein 6 
(DPPX) (Table 1).
Clinicians should be aware of formes frustes within these classical syndromes, for 
example some patients incipient NMDA-R encephalitis may present with first episode 
psychosis or prominent movement disorder.

































































Patients presenting with symptoms suggestive of encephalitis should be admitted 
urgently and undergo lumbar puncture and neuroimaging. The main concern at the 
outset is to exclude an infectious cause such as HSV, which can cause rapidly 
progressive brain oedema, necrosis and death. Aciclovir treatment in HSV 
encephalitis is a life-saving intervention.Several antibody-associated encephalitides, 
particularly NMDA-R encephalitis, can present similarly to primary psychiatric 
illness. “Red flag” early features for AE include an infectious prodrome, rapid 
progression, movement disorder, focal neurological signs, seizures or unexplained 
hyponatraemia.8 
Although autoimmune encephalitis is now usually a positive diagnosis, other mimics 
of AE should be excluded, including primary central nervous system (CNS) 
lymphoma, neurosarcoidosis, CNS vasculitis, tumours, genetic epilepsy syndromes, 
mitochondrial encephalomyopathies, and prion disease.
CSF findings are often abnormal in AE, with a mild lymphocytic pleocytosis and/or 
moderately raised CSF protein. However, a completely normal CSF occurs in up to a 
third of patients and does not exclude the diagnosis.9
Neuroimaging with magnetic resonance imaging (MRI) is essential, although this 
may also be normal in up to a third of cases.10 In general, MRI findings are 
nonspecific although medial temporal lobe signal change frequently occurs in limbic 
encephalitis (e.g. figure 1 A and B). 
Electroencephalography (EEG) often reveals encephalopathic changes which can 
support the diagnosis but are nonspecific. Caution is required as psychiatric and 
antiepileptic drugs can cause similar features.11 EEG is helpful in diagnosing non-
convulsive status epilepticus, or in distinguishing seizures (e.g. epilepsia partialis 
continua (EPC)) from a movement disorder. NMDA-R encephalitis may be 
associated with characteristic extreme delta brush pattern (figure 1 C).
Antibody testing for encephalitis is a rapidly evolving area of neuroimmunology. 
Certain autoimmune encephalitides, particularly those associated with NMDA-R and 
LGI1 antibodies, present with recognisable clinical syndromes and diagnostic 
suspicion may already be high so that antibody testing can be targeted. In other 
cases without distinguishing features, testing for a wider range of antibodies may be 
necessary, in consultation with a neurologist and neuroimmunology laboratory. 
Panels of immunofluorescence tests have been developed commercially and their 
role is still evolving, considering the balance between increased chance of detecting 
a pathogenic antibody versus the potential for false positives. Antibodies have 
hitherto mostly been tested in serum. However, intrathecal antibody synthesis occurs 
in most forms of AE and, particularly for NMDA-R antibodies, CSF testing is more 
sensitive and specific than serum and should be undertaken where clinical suspicion 
is high and in challenging cases. 
Consensus criteria also allow for a diagnosis of ‘seronegative AE’, based on clinical 
features in the absence of antibodies which may respond to immune therapy.6,12 (box 
1) 
































































Because of the paraneoplastic associations of several antibodies, investigation for 
malignancy is crucial. Computed tomography of the chest, abdomen, and pelvis is 
indicated in all patients with suspected AE. For those with particular associations, 
such as GABABR, positron emission tomography scanning is advised and, if 
negative, should be repeated at 3-6 months.13 Additionally, in NMDA-R encephalitis, 
because of the association with teratoma, ultrasound of the ovaries or testes should 
be performed.
4. Management and outcome
Evidence for optimal management of AE is largely based on retrospective studies, 
together with principles adapted from other antibody mediated diseases, e.g. 
myasthenia gravis. Patients with encephalitis should be managed at a centre with 
appropriate facilities and specialist expertise, ideally a regional neuroscience centre.
First line therapy, aimed at reducing antibody levels rapidly, normally comprises 
intravenous corticosteroids often in combination with intravenous immunoglobulin or 
plasma exchange. In those who fail to respond, more aggressive immune therapy is 
usually started, with concomitant higher risk of adverse effects, including 
cyclophosphamide or rituximab.14 In NMDA-R encephalitis other agents such as 
bortezomib have been used in a small number of refractory cases. Relapses may 
occur when immune therapy is reduced, or may reflect tumour recurrence or 
persistence of missed tumour.15
Starting immune therapy early has been associated with improved outcome in 
NMDA-R encephalitis in retrospective series. Also, in those who fail to respond to 
first-line therapy, moving to more aggressive second line treatments is associated 
with better outcome and reduced rate of relapse.16 In patients with ovarian teratoma, 
tumour resection is associated with faster rate of recovery and reduced relapse 
rate.16 
LGI1 encephalitis generally responds well to first-line treatment, particularly 
corticosteroids, and outcomes are generally good, however, in the long-term 
cognitive problems are common.17,18
Patients with autoimmune encephalitis often require extensive supportive care, 
including prolonged intensive care unit stays. Issues may include managing 
seizures, autonomic instability, infective complications, and agitation. Antipsychotic 
medications may be required, but should be used with caution due to the risk of 
extrapyramidal side effects or neuroleptic malignant syndrome, which may be higher 
in NMDA-R encephalitis.19
With appropriate treatment, outcome overall compares favourably with infectious 
encephalitis, with >80% of patients with NMDA-R encephalitis having no more than 
slight disability (modified Rankin Scale 2) at 2 years.16 However, evidence is 
emerging that subtle neurocognitive/psychosocial issues may be more prevalent 
than previously appreciated.20 Support from psychology/counselling services and 
charitable groups, such as the Encephalitis Society, is vital in the recovery phase. 

































































It is increasingly possible to make a positive diagnosis of AE given consensus 
clinical criteria and increased availability of antibody tests. However, this relies on a 
high index of suspicion, especially in those presenting with primarily psychiatric 
features. The diagnosis is often supported by the development of ‘neurological’ 
features, such as movement disorders and seizures, laboratory tests, and MRI, but 
these may be normal in some. Antibody testing should be organised in consultation 
with a neurologist and neuroimmunology laboratory, with a pragmatic strategy based 
on careful clinical assessment. Even in the absence of antibodies, it may be possible 
to make a syndromic diagnosis.
Many with AE have a good outcome with early immune therapy, tumour resection if 
needed, and supportive care. Randomised controlled trials are needed to guide 
treatment strategies.
Key points
Autoimmune encephalitis should be a key part of the differential diagnosis in patients 
with alterations in cognition, consciousness, personality, or behaviour.
Antibody testing should be guided by recognisable clinical syndromes, but also 
should account for the expanding numbers of recognised antibodies and overlapping 
phenotypes. 
Autoimmune encephalitis may present sub-acutely with normal or subtly abnormal 
CSF findings and neuroimaging.
Despite severe symptoms and long ITU stays, the outcome of AE is good in most 
cases if early immune therapy is given. 
The optimum first and second line treatment strategy for AE is unclear and well-
designed clinical trials are needed.  
Key words
Neuroimmunology, encephalitis, autoimmunity, NMDA-R encephalitis, limbic 
encephalitis.

































































































































1. A 72 year old man presented with a 3 month history of gradually worsening 
memory difficulties and unusual behaviour, including emotional lability. Family had 
noticed some jerky movements of his left arm and face on a few occasions over the 
preceding three weeks. On examination he was alert but distracted and his mini 
mental state examination (MMSE) score was 9/30. MRI brain showed age-
appropriate brain atrophy with T2 signal hyperintensity in the right medial temporal 
lobe. CSF showed white cell count of 8/mm3 (normal range <5), protein of 0.7 g/L 
(normal <0.5) with normal glucose ratio. Which antibody is most likely to be found in 







The patient had limbic encephalitis, with typically prominent memory and cognitive 
problems with a subacute onset and inflammation in the medial temporal lobe. The 
most common antibody identified in this situation is LGI1, and the jerky movements 
seen by his family are suspicious for faciobrachial dystonic seizures which may be 
pathognomonic for this disorder.
2. A 23 year old woman was referred from the psychiatric hospital for assessment of 
suspected seizures and hyperthermia. She had been an inpatient there for 6 weeks 
receiving treatment for a first episode of psychosis with neuroleptic medications. On 
clinical examination she was drowsy, had writhing movements of her left hand and 
was repeatedly protruding her tongue. Her temperature was 38.2oC and heart rate 
was 135. MRI brain was normal and CSF showed white cell count of 35 (normal 
range <5), protein of 0.4 g/L (normal range <0.5). CT scan of the chest, abdomen 
and pelvis revealed an ovarian mass. What is the most likely diagnosis?
A. Juvenile myoclonic epilepsy
B. LGI1 encephalitis 
C. NMDA-R encephalitis
D. Primary psychiatric diagnosis 


































































The combination of psychiatric features with autonomic instability, movement 
disorder and encephalopathy is characteristic of NMDA-R encephalitis. The 
presence of CSF pleocytosis, and an ovarian mass (most likely a teratoma) is also 
supportive, and the mass should be resected urgently. MRI brain is frequently 
normal in AE. Juvenile myoclonic epilepsy presents with myoclonus (which are not 
writhing movements) and generalised seizures. LGI1 encephalitis causes a limbic 
encephalitis, usually in older adults. Tardive dyskinesia would be unusual after only a 
few weeks of treatment and does not explain the addition features. 
3. A 52 year old woman, previously fit and well, presented to the emergency 
department with a 4 day history of flu-like illness and increasing drowsiness, with a 
single generalised tonic-clonic seizure. Her family reported that she had been 
agitated and aggressive when rousable. On examination her Glasgow coma scale 
(GCS) score was 10 (E3, V2, M5), she was moving all four limbs. CT brain showed 
subtle diffuse hypodensity in bilateral medial temporal lobes of uncertain aetiology, 
more prominent on the left. What is the most appropriate initial management?
A. Intravenous alteplase
B. Intravenous corticosteroids
C. Intravenous immunoglobulin 
D. Plasma exchange
E. Intravenous aciclovir 
Answer: E
In a patient with acute decrease in conscious level and seizures, infectious 
encephalitis (most commonly HSV encephalitis in the UK) is the most important 
diagnosis to rule out. Lumbar puncture (LP) should be performed urgently, and 
intravenous aciclovir (which decreases morbidity and mortality) should be given 
either immediately after the LP, or before if LP is delayed for any reason. 
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Psychiatric features followed by 
movement disorder (classically 
orofacial dyskinesia), seizures, 
encephalopathy and autonomic 
dysfunction
About 50% of female 












Sleep disorders (insomnia, sleep-
wake cycle disturbance), 
peripheral nerve hyperexcitability, 
ataxia 
<5%, various tumours
GABAAR Children or 
adults
1:1 Seizures Thymoma in 30%
GABABR Older adults 1:1.5 Seizures, amnesia SCLC in 50%
AMPAR Older adults 2:1 Amnesia 65%
Breast, SCLC, 
thymoma




NMDAR = N-methyl -aspartate receptor; LGI1 = leucine rich glioma inactived-1; CASPR2 = contactin-
associated protein-like 2; GABAAR = γ-aminobutyric acid type A receptor; GABABR = γ-aminobutyric 
acid type B receptor; AMPAR = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; 
DPPX = dipeptidyl-peptidase-like protein 6; SCLC = small cell lung cancer.
































































Box 1. Diagnostic criteria for possible autoimmune encephalitis 6
Diagnosis can be made when all three of the following criteria have been 
met:
1. Subacute onset (rapid progression of less than three months) of working 
memory deficits (short-term memory loss), altered mental status, or psychiatric 
symptoms.
2. At least one of the following:
 New focal CNS findings
 Seizures not explained by a previously known seizure disorder
 CSF pleocytosis
 MRI features suggestive of encephalitis
3. Reasonable exclusion of alternative causes (e.g. HSV encephalitis).
CNS = central nervous symptoms; CSF = cerebrospinal fluid; MRI = magnetic resonance 
imaging.

































































a) T2 weighted axial MRI of 55 year old male with LGI-1 antibody encephalitis showing high signal in the left 
medial temporal lobe. b) Coronal T2 FLAIR from the same patient showing high signal in the left medial 
temporal lobe. c) EEG of a patient with NMDA-R antibody encephalitis showing the characteristic finding of 
extreme delta brush 
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